Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX

Journal of Medicinal Chemistry

Volumn 49, Issue 18, 2006, Pages 5544-5551

  De Simone, Giuseppina ^a   Vitale, Rosa Maria ^a   Di Fiore, Anna ^a   Pedone, Carlo ^a,b   Scozzafava, Andrea ^c   Montero, Jean Louis ^d   Winum, Jean Yves ^d   Supuran, Claudiu T ^d  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d INSTITUT CHARLES GERHARDT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; DICLOFENAMIDE; ETHOXZOLAMIDE; GLUTAMINE; INDISULAM; ISOENZYME; LEUCINE; NITROGEN DERIVATIVE; PHENYLALANINE; PROLINE; PROPIONAMIDE DERIVATIVE; SULFONAMIDE; SULPIRIDE; THIOBENZAMIDE DERIVATIVE; THIOL DERIVATIVE; THREONINE; VALINE; ZINC ION; ZONISAMIDE;

ARTICLE; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; CYTOSOL; DISULFIDE BOND; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; HYPOXIA; MOLECULAR INTERACTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CRYSTALLOGRAPHY, X-RAY; DISULFIDES; ENZYME ACTIVATION; HUMANS; HYDROGEN BONDING; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PRODRUGS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; SULFONAMIDES;

EID: 33748541296     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060531j     Document Type: Article

References (58)

1. Pastorekova, S.; Pastorek, J. Cancer-Related Carbonic Anhydrase Isozymes. In Carbonic Anhydrase. Its Inhibitors and Activators; Supuran, C. T., Scozzafava, A., Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 253-280.
2. (a) Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inibitors. Med. Res. Rev. 2003, 23, 146-189.
3. (b) Supuran, C. T., Scozzafava, A., Conway, J., Eds. Carbonic Anhydrase. Its Inhibitors and Activators; CRC Press (Taylor and Francis Group): Boca Raton, FL, 2004; pp 1-363 and references therein.
4. (c) Casini, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets 2002, 2, 55-75.
5. (a) Wykoff, C. C.; Beasley, N. J.; Watson, P. H.; Turner, K. J.; Pastorek, J.; Sibtain, A.; Wilson, G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
6. (b) Potter, C. P. S.; Harris, A. L. Diagnostics, prognostics and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer 2003, 89, 2-7.
7. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62.
8. (a) Pastorek, J.; Pastorekova, S.; Callebaut, I.; Mornon, J. P.; Zelnik, V.; Opavsky, R.; Zatovicova, M.; Liao, S.; Portetelle, D.; Stanbridge, E. J.; Zavada, J.; Burny, A.; Kettmann, R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9, 2788-2888.
9. (b) Opavský, R.; Pastorekova, S.; Zelnik, V.; Gibadulinova, A.; Stanbridge, E. J.; Zavada, J.; Kettmann, R.; Pastorek, J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationship. Genomics 1996, 33, 480-487.
10. Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271-275.
11. Epstein, A. C. R.; Gleadle, J. M.; McNeil, L. A. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107, 43-54
12. Ratcliffe, P. J.; Pugh, C. W.; Maxwell, P. H. Targeting tumors through the HIF system. Nat. Med. 2000, 6, 1315-1316.
13. 2-regulated prolyl hydroxylation. Science 2001, 292, 468-472.
14. Harris, AL. Hypoxia, a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47.
15. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
16. Svastova, E.; Hulikova, A.; Rafajova, M.; Zatovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-445.
17. (a) Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastorekova, S.; Scozzafava, A.; Winum, J.-Y.; Montero, J.-L.; Supuran, C. T. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 2005, 48, 4834-4841.
18. (b) Casey, J. R.; Morgan, P. E.; Vullo, D.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 2004, 47, 2337-2347.
19. Vullo, D.; Franchi, M.; Gallon, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
20. (a) Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873.
21. (b) Winum, J. Y.; Scozzafava, A.; Montero, J. L.; Supuran, C. T. Sulfamates and their therapeutic potential. Med. Res. Rev. 2005, 25, 186-228.
22. (c) Winum, J. Y.; Scozzafava, A.; Montero, J. L.; Supuran, C. T. The sulfamide motif in the design of enzyme inhibitors. Expert Opin. Ther. Pat. 2006, 16, 27-47.
23. (a) Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 217-223.
24. (b) Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective Celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 47, 550-557.
25. (c) Abbate, F.; Casini, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide. Bioorg. Med. Chem. Lett. 2004, 14, 2357-2361.
26. Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A, Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg. Med. Chem. 2001, 9, 703-714.
27. Parkkila, S.; Rajaniemi, H.; Parkkila, A. K.; Kivela, J.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2220-2224.
28. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran C. T. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
29. (a) Denny, W. A. Tumor-activated prodrugs. A new approach to cancer therapy. Cancer Invest. 2004, 22, 604-619.
30. (b) Stratford, I. J.; Williams, K. J.; Cowen, R. L.; Jaffar, M. Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin. Radiat. Oncol. 2003, 13, 42-52.
31. (c) Frein, D.; Schildknecht, S.; Bachschmid, M.; Ullrich, V. Redox regulation: a new challenge for pharmacology. Biochem. Pharmacol. 2005, 70, 811-823.
32. (d) Garber, K. New drugs target hypoxia response in tumors. J. Natl. Cancer Inst. 2005, 97, 1112-1114.
33. Hay, M. P.; Pruijn, F. B.; Gamage, S. A.; Liyanage, H. D.; Kovacs, M. S.; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. J. Med. Chem. 2004, 47, 475-488.
34. Seow, H. A.; Penketh, P. G.; Shyam, K.; Rockwell, S.; Sartorelli, A.C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)-ethoxy]carbonyl] hydrazine: an anticancer agent targeting hypoxic cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9282-9287.
35. Nomura, M.; Shuto, S.; Matsuda, A. Synthesis of the cyclic and acyclic acetal derivatives of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, a potent antitumor nucleoside. Design of prodrugs to be selectively activated in tumor tissues via the bio-reduction-hydrolysis mechanism. Bioorg. Med. Chem. 2003, 11, 2453-2461.
36. Phillips, R. M.; Jaffar, M.; Maitland, D. J.; Loadman, P. M.; Shnyder, S. D.; Steans, G.; Cooper, P. A.; Race, A.; Patterson, A. V.; Stratford, I. J. Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Biochem. Pharmacol. 2004, 68, 2107-2116.
37. (a) Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146-89.
38. (b) Supuran, C. T.; Scozzafava, A.; Casini, A., Development of Sulfonamide Carbonic Anhydrase Inhibitors. In Carbonic Anhydrase. Its Inhibitors and Activators; Supuran, C. T., Scozzafava, A., Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 67-147.
39. Welsh, S. J.; Williams, R. R.; Birmingham, A.; Newman, D. J.; Kirkpatrick, D. L.; Powis, G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1-alpha and vascular endothelial growth factor formation. Mol. Cancer Ther. 2003, 2, 235-243.
40. (a) Scozzafava, A.; Menabuoni, L.; Mincione, F.; Briganti, F.; Mincione, G.; Supuran, C. T. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J. Med. Chem. 1999, 42, 2641-2650.
41. (b) Winum, J. Y.; Dogne, J. M.; Casini, A.; de Leval, X.; Montero, J. L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J. Med. Chem. 2005, 48, 2121-2125.
42. Turpin, J. A.; Song, Y.; Inman, J. K.; Huang, M.; Wallqvist, A.; Maynard, A.; Covell, D. G.; Rice, W. G.; Appella, E. Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers. J. Med. Chem. 1999, 42, 67-86.
43. (a) Innocenti, A.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with anions isosteric and isoelectronic with sulfate, nitrate and carbonate. Bioorg. Med. Chem. Lett. 2005, 15, 567-571.
44. (b) Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions. J. Enzyme Inhib. Med. Chem. 2003, 18, 403-406.
45. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 2561-2573.
46. Eriksson, A. E.; Jones, T. A.; Liljas, A. Refined structure of human carbonic anhydrase II at 2.0 Å resolution. Proteins: Struct., Funct., Genet. 1988, 4, 274-282.
47. Brünger, A. T.; Adams, P. D.; Clore, G. M.; De Lano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921.
48. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
49. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr., Sect. A 1991, 47, 110-119.
50. Alterio, V.; Vitale, R. M.; Monti, S. M.; Pedone, C.; Scozzafava, A.; Cecchi, A.; De Simone, G.; Supuran, C. T. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 2006, 128, 8329-8335.
51. Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. S.; Cheatham, T. E., III.; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. "AMBER", a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to stimulate the structural and energetic properties of molecules. Comput. Phys. Commun. 1995, 91, 1-42.
52. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074.
53. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97, 10269-10280.
54. Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A. General atomic and molecular electronic structure system. J. Comput. Chem. 1993, 14, 1347-1363.
55. Suarez, D.; Merz, K. M., Jr. Molecular dynamics simulations of the mononuclear zinc-beta-lactamase from Bacillus cereus. J. Am. Chem. Soc. 2001, 123, 3759-3770.
56. Hoops, S. C.; Anderson, K. W.; Merz, K. M., Jr. Force field design for metalloproteins. J. Am. Chem. Soc. 1991, 113, 8262-8270.
57. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. C. J. Comput. Phys. 1977, 23, 327-341.
58. Koradi, R.; Billeter, M.; Wuethrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics 1996, 14, 51-55, plates 29-32.